Global EditionASIA 中文双语Français
Home / Business / Companies

Sinovac begins trials on Omicron vaccine booster in HK

By Liu Zhihua | | Updated: 2022-07-05 14:42
Share - WeChat
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. [Photo/Xinhua]

Chinese vaccine producer Sinovac Biotech officially kicked off a clinical trial in Hong Kong on Monday to assess the safety and immunogenicity of its Omicron-specific COVID-19 inactivated vaccine which will be used as a booster shot in healthy adults.

The trial program plans to recruit around 300 or more healthy volunteers who are above the age of 18 and who have already been inoculated with two or three shots of either inactivated or mRNA COVID-19 vaccine.

This study is being led by a research team from the University of Hong Kong Clinical Trials Centre in collaboration with Gleneagles Hospital Hong Kong.

Sinovac obtained a sample of the Omicron variant in early December last year to further the research and development of its Omicron-specific inactivated COVID-19 vaccine.

Preclinical studies have showed the vaccine is safe and effective on animals, the company said.

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349